Understand the source comparison
Tesofensine vs GLP-1 Medications: Research Comparison
Tesofensine 1.0mg daily 12.8% mean reduction Dry mouth (54%), insomnia (21%), increased heart rate (+7–10 bpm) Elevated BP and HR. Contraindicated in hypertension or arrhythmias Not FDA-approved; available through research suppliers Effective non-incretin alte
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Tesofensine 1.0mg daily
- 12.8% mean reduction
- Dry mouth (54%), insomnia (21%), increased heart rate (+7–10 bpm)
- Elevated BP and HR. Contraindicated in hypertension or arrhythmias
- Not FDA-approved; available through research suppliers
- Effective non-incretin alternative for stimulant-tolerant individuals without cardiovascular risk factors
- Semaglutide 2.4mg weekly
- 14.9% at 68 weeks (extrapolates to ~5% at 24 weeks)
- Nausea (44%), vomiting (24%), diarrhea (30%) during titration
- Neutral to slightly protective. Reduced MACE in SUSTAIN-6 cardiovascular outcomes trial
- FDA-approved (Wegovy)
- Gold standard for patients with metabolic syndrome or type 2 diabetes; GI side effects limit tolerability
- Tirzepatide 15mg weekly
- 20.9% at 72 weeks (extrapolates to ~7% at 24 weeks)
- Similar GI profile to semaglutide but slightly higher incidence
- Cardiovascular outcomes trial (SURPASS-CVOT) ongoing; interim data suggests benefit
- FDA-approved (Zepbound)
- Highest efficacy among current options; dual GLP-1/GIP agonism produces superior weight loss with manageable side effects
- Phentermine 37.5mg daily
- 5–7% at 12 weeks
- Insomnia, dry mouth, constipation, elevated HR/BP
- Significant sympathomimetic effects. Short-term use only due to cardiovascular risk
- FDA-approved (short-term use only)
- Legacy stimulant with established efficacy but unfavorable long-term safety profile